14 published brand profiles in this category. Cite the individual brand profile for brand-specific facts.
AbCellera - AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office.
Adagio Therapeutics - Adagio Therapeutics is a antibody therapeutics brand headquartered in Waltham, MA, founded in 2020.
ADC Therapeutics - Prior to ADC Therapeutics, Mr. Carmona was the CFO at Rubius Therapeutics, a biopharmaceutical company engineering red blood cells to create a new class of cellular medicines for cancer and autoimmune diseases. Before joining Rubius Therapeutics, he was the CFO of Radius Health, a global commercial company specializing in bone health.
Adimab - At Adimab, science meets collaboration. We partner to discover and engineer protein therapeutics that make a real difference in patients’ lives.
Affimed - Affimed is a antibody therapeutics brand headquartered in Heidelberg, Germany, founded in 2000.
Apexigen - Apexigen is a antibody therapeutics brand headquartered in San Carlos, CA, founded in 2009.
Bioverativ - Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta (acquired by Shire Plc in 2016), Pfizer and Novo Nordisk.
Harbour Antibodies - Harbour Antibodies is an antibody therapeutics company headquartered in Rotterdam, Netherlands, founded in 2017.
Harbour BioMed - Harbour BioMed is an antibody therapeutics company headquartered in Shanghai, China, founded in 2016.
I-Mab - I-Mab is an antibody therapeutics company headquartered in Shanghai, China, founded in 2016.
Merus - At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer.
Morphosys - Reimagining medicine, together. For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medicines that redefine the future for patients.
Xencor - Xencor is expanding the therapeutic boundaries of antibody drugs. Powered by its XmAb® protein engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and other serious diseases. More than 20 programs are in clinical testing, and many more are in preclinical development.
Zymeworks - In addition, Zymeworks is supporting the early-stage development of innovative medicines to contribute to a portfolio of healthcare assets that can be partnered to generate strong cash flows. Our proprietary, complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated multifunctional antibody-based therapeutics for ourselves and our partners. Our platforms’ versatility enables c